ForeSentia tumour molecular profile – basic panel of 80 genes

What is the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test – Basic Panel of 80 Genes?

ForeSENTIA Pan-Cancer is an advanced oncogenetic test that enables comprehensive molecular profiling of tumors, identifying a wide range of genetic alterations and one of the key genomic biomarkers – microsatellite instability (MSI¹). This information helps tailor targeted therapies to the individual needs of the patient.

¹ MSI – Microsatellite Instability

Who is the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test for?

The test is intended for individuals diagnosed with malignant tumors. It is particularly recommended for:

• Patients who need genetic testing to qualify for targeted therapy.
• Patients with therapy resistance or cancer recurrence who are seeking alternative treatment options, including immunotherapy.
• Patients who wish to enhance the chances of selecting effective treatment through biomarker testing related to immunotherapy (MSI).

How to prepare for the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test?

No special preparation is required. Patients must submit paraffin-embedded tissue blocks collected during surgery (with slides). No referral is needed.

The test can be conducted within 3 months from the purchase date (as stated in the order confirmation).

How does the ForeSENTIA Pan-Cancer test process work?

1. Contact our team – leave your contact details via the online form. We will reach out to you within 2 business days to explain the next steps.

Before the tumor tissue genetic test:

• Purchase the histopathological assessment service and send us the paraffin blocks – tissue samples fixed in formalin and embedded in paraffin collected during biopsy or surgery.
• The sample will be evaluated to determine the percentage of cancer cells and assess its suitability for genetic testing.
• Upon positive evaluation, the specialist will prepare the sample for genetic analysis.

We also recommend reviewing the Patient Instructions available in the "Documents" section, which explain the test process in detail.

2. Purchase the ForeSENTIA Pan-Cancer Test – you can buy the test online or at a Damian Medical Center location.
3. Sample dispatch – the prepared sample is sent to a genetic laboratory.
4. Laboratory analysis – the sample undergoes advanced genetic testing at the Medicover Genetics laboratory.
5. You will receive the results within 30 days from the sample's arrival at the lab. The test report will be emailed to you.
6. FREE ONCOLOGY CONSULTATION – within 3 months of receiving the report, you may consult an oncologist to discuss the results.

How long does it take to receive the results and how to interpret them?

The test report (in Polish) will be emailed within 30 business days from the sample's arrival at the laboratory.

Note that interpreting genetic results requires consideration of the patient’s complete clinical picture.

A comprehensive report will be prepared, including a detailed interpretation and classification of detected genetic alterations and biomarkers in accordance with the latest guidelines. The report also provides updated information on available therapeutic options, enabling treatment to be precisely tailored based on the genetic profile of the tumor.

The test report includes:

• Assessment of the MSI immunotherapy biomarker status
  MSI status is presented along with FDA²/EMA³-approved immunotherapies.
• Genetic variant analysis results
  Identified variants of strong, potential, and uncertain significance are reported along with FDA/EMA-approved or NCCN⁴-recommended targeted therapies, including:
  • Approved therapies matching the patient’s diagnosis
  • Therapies listed in NCCN guidelines
  • Variants linked to lack of treatment response
• Eligibility for clinical trials
  The report includes current clinical trials, expanding the patient’s treatment options. Results are presented clearly and comprehensively to support therapeutic decision-making.

² FDA – Food and Drug Administration

³ EMA – European Medicines Agency

⁴ NCCN – National Comprehensive Cancer Network®

How Can the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test – Basic Panel of 80 Genes Help You?

The ForeSENTIA Pan-Cancer test provides crucial insights that support the cancer treatment process:

• Enables simultaneous analysis of clinically significant genetic alterations and the immunotherapy biomarker (MSI) in a single test.
• Covers genes recommended by international oncology societies and considered in ongoing clinical trials.
• Assesses tumor-agnostic biomarkers, increasing the applicability across cancer types.
• Supports the selection of targeted therapies, including immunotherapy, that effectively target cancer cells with minimal impact on healthy tissues.
• Helps avoid ineffective treatment methods that could unnecessarily burden the patient’s body.
• Provides information on available clinical trials the patient may qualify for, increasing access to modern, often innovative therapies.

Why Choose the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test – Basic Panel of 80 Genes?

ForeSENTIA Pan-Cancer is a comprehensive genetic diagnostic tool that allows precise identification of a tumor’s molecular profile. Through broad genetic analysis, it supports the selection of the most suitable treatment and increases the chances of effective therapy.

Learn more and schedule your test today!

The test is performed by Medicover Genetics (Cyprus) – a laboratory with many years of experience.

NGS Test Technical Information:

A unique process combining proprietary Targeted Capture Enrichment Technology, next-generation sequencing (NGS), and advanced bioinformatics algorithms ensures precise detection of genetic variants within the ForeSENTIA Pan-Cancer test.

The test detects clinically relevant genetic alterations, including:

• • Single nucleotide variants (SNVs)
• • Insertions and deletions (INDELs)
• • Copy number alterations (CNAs)
• • Rearrangements

The test analyzes selected regions of 80 genes⁵.

The ForeSENTIA test also evaluates the immunotherapy biomarker – microsatellite instability (MSI).

⁵ The 1p/19q codeletion is also analyzed in this panel, but only in the context of glioma diagnosis.

Genetic Alterations Detected in the ForeSENTIA Pan-Cancer Test (80 Genes):

SNVs/INDELs:

AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CHEK2, CIC, CTNNB1, DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, FOXA1, FOXL2, FUBP1, GATA3, GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, MYC, MYCN, NBN, NF1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PDGFRA, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RB1, RET, ROS1, RUNX1, SMAD4, SPOP, STK11, TERT, TMPRSS2, TP53

CNAs:

1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53

Rearrangements:

ALK, BRAF, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2

Where to Perform the ForeSENTIA Pan-Cancer Tumor Molecular Profile Test – Basic Panel of 80 Genes?

The ForeSENTIA Pan-Cancer test is available at Damian Medical Center facilities. Check available locations and schedule your appointment today!